LCD, Billing and Coding Article Updates for November-December 2022

New LCDs and Articles (Effective 11/1/2022)

Off-Label Use of Intravenous Immune Globulin (IVIG) – (L39314)

This LCD addresses off-label uses for IVIG. We define off-label as not in Medicare approved compendia or in the FDA label. Labeled indications continue to be covered.

Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG) – (A59105)

This article addresses off-label uses for IVIG. We define off-label as not in Medicare approved compendia or in the FDA label.

Off-label Use of Rituximab and Rituximab Biosimilars – (L39297)

This policy addresses the off-labeled use of rituximab for non-anti-neoplastic conditions. The use of rituximab for labeled indications is covered and not addressed in this policy. Off-label use for anti-neoplastic therapy is not addressed in this policy.

Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars – (A59101)

This article defines off-label, non-compendia approved, uses for Rituximab.

Retired Billing and Coding Articles

• Billing and Coding: Intravenous Immune Globulin (IVIG) – (A52446)
• Billing and Coding: Nivolumab – (A54862)
• Billing and Coding: Complex Drug Administration Coding – (A58620)
• Billing and Coding: Filgrastim, Pegfilgrastim, Tbo-filgrastim and biosimilars – (A52408)
• Billing and Coding: Rituximab, biosimilars and Rituximab and hyaluronidase human (Rituxan Hycela™) – (A52452)

Revised LCDs and Billing and Coding Articles:

Cardiovascular Nuclear Medicine – (L33560)

Removed duplicate entry for "Assessment of congenital anomalies of coronary arteries;" from Indications of Coverage.

Billing and Coding: Cardiovascular Nuclear Medicine – (A56743)

ICD-10-CM code I44.7 has been added to Group 1 covered diagnoses.

Revised 11/23/2022